CRISPR Therapeutics AG (CRSP) Enterprise Value (2016 - 2025)
Historic Enterprise Value for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$2.0 billion.
- CRISPR Therapeutics AG's Enterprise Value fell 378.18% to -$2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.0 billion, marking a year-over-year decrease of 378.18%. This contributed to the annual value of -$2.0 billion for FY2025, which is 378.18% down from last year.
- Latest data reveals that CRISPR Therapeutics AG reported Enterprise Value of -$2.0 billion as of Q4 2025, which was down 378.18% from -$1.9 billion recorded in Q3 2025.
- CRISPR Therapeutics AG's 5-year Enterprise Value high stood at -$1.7 billion for Q4 2023, and its period low was -$2.6 billion during Q2 2021.
- In the last 5 years, CRISPR Therapeutics AG's Enterprise Value had a median value of -$1.9 billion in 2024 and averaged -$2.0 billion.
- As far as peak fluctuations go, CRISPR Therapeutics AG's Enterprise Value crashed by 17399.57% in 2021, and later soared by 2369.82% in 2022.
- Over the past 5 years, CRISPR Therapeutics AG's Enterprise Value (Quarter) stood at -$2.4 billion in 2021, then rose by 23.7% to -$1.8 billion in 2022, then grew by 6.7% to -$1.7 billion in 2023, then dropped by 12.41% to -$1.9 billion in 2024, then decreased by 3.78% to -$2.0 billion in 2025.
- Its Enterprise Value stands at -$2.0 billion for Q4 2025, versus -$1.9 billion for Q3 2025 and -$1.7 billion for Q2 2025.